Breaking South Korea and U.S. Troops to Commence Annual Joint Military Drills Amid North Korean Missile Activity Andy Green Aims for New Land Speed Record with Hydrogen-Powered Vehicle Fashion Retailers Embrace Repair Services and Workshops to Attract Sustainability-Conscious Gen Z Asian Shares Mixed as Nikkei Leads Gains; Oil Prices Rise New Zealand Electoral Commission Urges Voter Registration Ahead of Deadline

Monday August 10, 2026

Reporter

Johnson & Johnson

2Articles Published

5Communities Covered

Published Articles

Press Release

Johnson & Johnson’s RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer

Jul 30

Press Release

TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma

Jul 23